Anti-Human CD166 (ALCAM) – Dylight® 650

Home/Primary Monoclonal Antibodies/Anti-Human CD166 (ALCAM) – Dylight® 650

Anti-Human CD166 (ALCAM) – Dylight® 650

Product No.: C722

Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
CD6 ligand, Activated Leukocyte Cell Adhesion Molecule (ALCAM)
IgG1 κ
IF Microscopy

Product Size

Antibody Details

Product Details

Reactivity Species
Host Species
Cultured human thymic epithelial cells
Product Concentration
0.2 mg/ml
This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This DyLight® 650 conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
Excitation Laser
Red Laser (652 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
Additional Applications Reported In Literature ?
IF Microscopy
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


3A6 activity is directed against human CD166 (ALCAM) and cross-reacts with ovine tissues.
Antigen Distribution
CD166 is expressed on neurons, activated leukocytes, hematopoietic stem cells, mesenchymal stem cells, bone marrow stromal cells, activated T cells, activated B cells, activated monocytes, thymic epithelial cells, vascular endothelial cells, fibroblasts, keratinocytes, myeloid progenitors, tumor cells, and cancer stem cells.
Activated leukocyte cell adhesion molecule (ALCAM) is a member of the immunoglobulin superfamily and a cell surface glycoprotein1. In normal physiology, ALCAM functions in cell adhesion, is known to promote T cell activation and proliferation by interacting with CD6, and functions in angiogenesis, monocyte transmigration, leukocyte intravasation across the blood-brain barrier, hematopoiesis, neurite extension, osteogenesis, and embryonic implantation in the uterus. In cancer, ALCAM is a prognostic marker of disease progression and acts as a modulator of progression by controlling cell proliferation, adhesion, migration, and invasion.

ALCAM participates in homophilic ALCAM-ALCAM interactions as well as numerous heterophilic interactions1. Ligands include CD6, galectin-8, endophilin-A3/galectin-8, CD9, S100B, and ezrin. Additionally, SOSTDC1 is a novel ligand of ALCAM that promotes invasion and facilitates liver metastasis in colorectal cancer through activation of the Src-P13K/AKT pathways2.

ALCAM is a type I transmembrane molecule with a large glycosylated extracellular domain1. Two isoforms have been confirmed at the protein level: ALCAM-Iso1, which is the full length isoform, and ALCAM-Iso2, which lacks exon 13. ALCAM is proteolytically cleaved at its extracellular domain by the transmembrane metalloprotease ADAM17, with ALCAM-Iso2 more susceptible to cleavage.

3A6 was produced by immunizing mice with human thymic epithelial cells and then fusing spleen cells with P3X63Ag8 myeloma cells3. 3A6 cross reacts with ovine mesenchymal stromal cells from iliac crest bone marrow aspirates4.
NCBI Gene Bank ID

References & Citations

1. Ferragut F, Vachetta VS, Troncoso MF, et al. Cytokine Growth Factor Rev. 61:27-37. 2021.
2. Bartolomé RA, Pintado-Berninches L, Jaén M, et al. Oncogene. 39(38):6085-6098. 2020.
3. Patel DD, Fong AM, Mann KP, et al. CD166 Workshop: Tissue distribution and functional analysis of antibodies reactive for CD166, a ligand for CD6. In: Kishimoto T, editor. Leukocyte Typing IV. Oxford: Oxford University Press; 1997. P.461-464.
4. Sanjurjo-Rodríguez C, Castro-Viñuelas R, Hermida-Gómez T, et al. PLoS One. 12(1):e0171231. 2017.
5. Piazza T, Cha E, Bongarzone I, et al. J Cell Sci. 118(Pt 7):1515-1525. 2005.
6. Tondreau T, Dejeneffe M, Meuleman N, et al. BMC Genomics. 9:166. 2008.
7. Srouji S, Kizhner T, Ben David D, et al. Calcif Tissue Int. 84(2):138-145. 2009.
8. Katsube Y, Kotobuki N, Tadokoro M, et al. Gene Ther. 17(4):494-502. 2010.
9. Brune JC, Tormin A, Johansson MC, et al. Int J Cancer. 129(2):319-330. 2011.
10. Ali H, Al-Yatama MK, Abu-Farha M, et al. PLoS One. 10(4):e0122465. 2015.
11. Prins HJ, Schulten EA, Ten Bruggenkate CM, et al. Stem Cells Transl Med. 5(10):1362-1374. 2016.
12. Fridriksdottir AJ, Kim J, Villadsen R, et al. Nat Commun. 6:8786. 2015.
13. Gong B, Zheng L, Lu Z, et al. Mol Med Rep. 23(1):43. 2021.
14. Yeh SP, Chang JG, Lin CL, et al. Leukemia. 19(8):1505-1507. 2005.
15. Levesque MC, Heinly CS, Whichard LP, et al. Arthritis Rheum. 41(12):2221-2229. 1998.
16. Ishiguro F, Murakami H, Mizuno T, et al. J Thorac Oncol. 7(5):890-899. 2012.
17. Bhattacharya S, Mathew G, Ruban E, et al. J Proteome Res. 9(12):6112-6125. 2010.
Flow Cytometry
Immunoprecipitation Protocol
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy. Ok